	Maximum Grade Per Patient Per Event (At least possibly related)									
	Grade of Adverse Event									
	1- Mild		2- Mod		3-Severe		4-LifeThr		5-Lethal	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Dose Escalation Cohort: Dose Level 1 (3 mg)										
Number of Evaluable Patients: 3										
Hematologic Adverse Events										
Blood/Bone Marrow										
Anemia	1	(33%)	1	(33%)	0	(0%)	0	(0%)	0	(0%)
Neutrophil count decreased	0	(0%)	3	(100%)	0	(0%)	0	(0%)	0	(0%)
Platelet count decreased	2	(67%)	0	(0%)	0	(0%)	0	(0%)	0	(0%)
White blood cell decreased	0	(0%)	2	(67%)	1	(33%)	0	(0%)	0	(0%)
Non-Hematologic Adverse Events										
Infections and infestations										
Lung infection	0	(0%)	0	(0%)	0	(0%)	1	(33%)	0	(0%)
Respirat, thor, mediast disord										
Respiratory failure	0	(0%)	0	(0%)	0	(0%)	1	(33%)	0	(0%)
Dose Escalation Cohort: Dose Level 2 (5 mg)										
Number of Evaluable Patients: 6										
Hematologic Adverse Events										
Blood/Bone Marrow										
Anemia	3	(50%)	2	(33%)	1	(17%)	0	(0%)	0	(0%)
Lymphocyte count decreased	0	(0%)	1	(17%)	0	(0%)	1	(17%)	0	(0%)
Neutrophil count decreased	1	(17%)	2	(33%)	2	(33%)	1	(17%)	0	(0%)
Platelet count decreased	2	(33%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
White blood cell decreased	1	(17%)	1	(17%)	1	(17%)	1	(17%)	0	(0%)
Non-Hematologic Adverse Events										
Eye disorders										
Eyelid function disorder	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Gastrointestinal disorders										
Constipation	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Mucositis oral	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Gen disord and admin site cond										
Fatigue	1	(17%)	1	(17%)	1	(17%)	0	(0%)	0	(0%)
Infections and infestations										
Bronchial infection	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Metabol and nutrition disord										
Hyperglycemia	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Nervous system disorders										
Syncope	0	(0%)	0	(0%)	1	(17%)	0	(0%)	0	(0%)
Skin and subcutan tiss disord										
Rash maculo-papular	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Vascular disorders										
Thromboembolic event	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Dose Escalation Cohort: Dose Level 3 (7 mg)										
Number of Evaluable Patients: 6										
Hematologic Adverse Events										
Blood/Bone Marrow										
Anemia	2	(33%)	2	(33%)	0	(0%)	0	(0%)	0	(0%)
Lymphocyte count decreased	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Neutrophil count decreased	1	(17%)	4	(67%)	0	(0%)	0	(0%)	0	(0%)
Platelet count decreased	1	(17%)	0	(0%)	0	(0%)	1	(17%)	0	(0%)
White blood cell decreased	1	(17%)	1	(17%)	1	(17%)	0	(0%)	0	(0%)
Non-Hematologic Adverse Events										
Gen disord and admin site cond										
Fatigue	0	(0%)	1	(17%)	1	(17%)	0	(0%)	0	(0%)
Infections and infestations										
Bronchial infection	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Infections and infestations - Oth spec	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Lung infection	0	(0%)	1	(17%)	1	(17%)	0	(0%)	0	(0%)
Mucosal infection	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Sepsis	0	(0%)	0	(0%)	0	(0%)	1	(17%)	0	(0%)
Investigations										
Aspartate aminotransferase increased	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Blood bilirubin increased	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Metabol and nutrition disord										
Anorexia	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Hypocalcemia	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Hypophosphatemia	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Nervous system disorders										
Peripheral sensory neuropathy	1	(17%)	0	(0%)	0	(0%)	0	(0%)	0	(0%)
Psychiatric disorders										
Delirium	0	(0%)	1	(17%)	0	(0%)	0	(0%)	0	(0%)
Respirat, thoracic, mediastinal disorders										
Dyspnea	0	(0%)	0	(0%)	1	(17%)	0	(0%)	0	(0%)
Hypoxia	0	(0%)	0	(0%)	1	(17%)	0	(0%)	0	(0%)
Respiratory failure	0	(0%)	0	(0%)	0	(0%)	1	(17%)	0	(0%)
MTD Expansion Cohort (Dose- 5 mg)										
Number of Evaluable Patients: 9										
Hematologic Adverse Events										
Blood/Bone Marrow										
Anemia	4	(44%)	3	(33%)	1	(11%)	0	(0%)	0	(0%)
Lymphocyte count decreased	0	(0%)	2	(22%)	1	(11%)	0	(0%)	0	(0%)
Neutrophil count decreased	1	(11%)	3	(33%)	1	(11%)	1	(11%)	0	(0%)
Platelet count decreased	3	(33%)	0	(0%)	1	(11%)	0	(0%)	0	(0%)
White blood cell decreased	3	(33%)	1	(11%)	0	(0%)	1	(11%)	0	(0%)
Non-Hematologic Adverse Events										
Endocrine disorders										
Hypothyroidism	0	(0%)	1	(11%)	0	(0%)	0	(0%)	0	(0%)
Gastrointestinal disorders										
Diarrhea	2	(22%)	0	(0%)	0	(0%)	0	(0%)	0	(0%)
Dyspepsia	0	(0%)	1	(11%)	0	(0%)	0	(0%)	0	(0%)
Nausea	1	(11%)	0	(0%)	0	(0%)	0	(0%)	0	(0%)
Gen disord and admin site cond										
Fatigue	0	(0%)	5	(56%)	0	(0%)	0	(0%)	0	(0%)
Infections and infestations										
Lung infection	0	(0%)	1	(11%)	1	(11%)	0	(0%)	0	(0%)
Upper respiratory infection	0	(0%)	1	(11%)	0	(0%)	0	(0%)	0	(0%)
Nervous system disorders										
Peripheral sensory neuropathy	0	(0%)	1	(11%)	0	(0%)	0	(0%)	0	(0%)
Skin and subcutan tiss disord										
Photosensitivity	0	(0%)	1	(11%)	0	(0%)	0	(0%)	0	(0%)
Rash maculo-papular	0	(0%)	0	(0%)	1	(11%)	0	(0%)	0	(0%)
Vascular disorders										
Thromboembolic event	0	(0%)	1	(11%)	0	(0%)	0	(0%)	0	(0%)